Organ-on-Chip Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Liver, Heart, Lung, Kidney, Others), By Offering (Products v/s Services), By Material Type (Polymer, PDMS, Glass, Silicon, Others), By Application (Physiological Model Development, Drug Discovery, Toxicological Research, Molecular Biology, Others), By End User (Pharmaceutical & Biote
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationOrgan-on-Chip Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Liver, Heart, Lung, Kidney, Others), By Offering (Products v/s Services), By Material Type (Polymer, PDMS, Glass, Silicon, Others), By Application (Physiological Model Development, Drug Discovery, Toxicological Research, Molecular Biology, Others), By End User (Pharmaceutical & Biote
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 388.20 Million |
| CAGR (2023-2028) | 25.61% |
| Fastest Growing Segment | Pharmaceutical & Biotechnology Companies |
| Largest Market | North America |
Market Overview
Global Organ-on-Chip Market has valued at USD 388.20 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 25.61% through 2028. Organs-on-chip are sophisticated artificial replicas of human organs. These cutting-edge devices utilize multichannel 3D microfluidic cell culture technology to faithfully mimic organ functions, processes, and physiological responses. By combining labs-on-chips (LOCs) with cell biology, researchers have successfully created a novel model of in vitro multicellular human beings, allowing for the analysis of human physiology within organ-specific environments.
These chips feature intricately designed microchannels that facilitate blood and air flow, enabling the simulation of various organs such as the lung, intestine, brain, liver, and heart. The microchips are populated with live cells, fostering tissue and organ function through constant perfusion. Organ-on-chip technology, with its unique blend of silicone nourishment, tissue engineering, and microfluidics, has the potential to revolutionize the field. These advancements hold great promise in addressing longstanding challenges in drug discovery and disease treatment, making it a crucial component in drug development investigations and propelling the organ-on-chip industry forward.
Key Market Drivers
Growing Demand of Miniaturization of Electronic Chips
The growing prevalence for microchips in the field of medical devices is a direct result of remarkable technological advancements. These advancements have not only fueled the demand for such devices but also paved the way for significant improvements in their construction and maintenance. The process of miniaturization has played a key role in achieving these advancements, as it allows for the reduction of materials required to build and sustain the system.
Moreover, the utilization of microfluidic chips has revolutionized the development of miniaturized tissues, enabling the simulation of real tissue in organ-on-a-chip systems. By creating an in vitro environment at the microscopic scale, these microfluidic chips effectively mimic the function and structure of actual organs. This breakthrough technology holds tremendous promise in advancing our understanding of organ function and disease progression. The integration of microchips and microfluidic chips in medical devices marks a significant milestone in the field of healthcare. With continued research and innovation, we can expect even greater advancements in this fascinating area, ultimately leading to improved diagnostics, treatments, and overall patient care.
Rising Healthcare Expenditure in Developed Countries
The rising prevalence of chronic diseases and an expanding elderly patient population are expected to drive up demand for market growth. The increasing burden of chronic conditions and the aging population necessitate a greater need for healthcare services and products. Moreover, rising healthcare expenditures in many countries, driven by factors such as advancements in medical technologies and an increasing focus on preventive care, are expected to further fuel the market in the approaching years. As a result, an exponential increase in the number of patients seeking treatment is anticipated, leading to a significant surge in product demand over the projection period.
For instance, in February 2019, a comprehensive report by the World Health Organization (WHO) on global health expenditure highlighted a rapid upward trajectory in healthcare spending, particularly noticeable in low and middle-income countries. These regions have been witnessing an average annual growth rate of 6%, compared to 4% in high-income countries. This trend underscores the growing recognition of the importance of healthcare and the need for increased investments to address the healthcare needs of the population.
Increasing Use an Alternative for Animal Testing
The increasing need for alternatives to animal testing is driving the growth of the global organ-on-chip market in the forecast period. Concerns about the ethical treatment of animals have led to a paradigm shift in scientific research. According to the People for the Ethical Treatment of Animals (PETA), each year, more than 110 million animals, including rats, fish, rabbits, dogs, frogs, monkeys, hamsters, mice, cats, guinea pigs, and birds, are sacrificed in U.S. laboratories for various purposes such as biology studies, medical internships, curiosity-driven investigations, and testing of chemicals, pharmaceuticals, food, and cosmetics.
A Pew Research Center poll revealed that 52% of U.S. adults oppose the use of animals in scientific research. Other surveys indicate that the remaining group that supports animal research does so because they believe it is necessary for medical progress. However, it is important to note that the majority of animal studies do not significantly contribute to improving human health. The role that animal research plays in most medical advancements is a subject of debate and controversy. These concerns have led to a growing demand for alternative testing methods, such as organ-on-chip technology. Organ-on-chip devices aim to replicate the functions of human organs, providing a more accurate and humane approach to studying diseases and testing potential treatments. As the awareness and support for alternatives to animal testing continue to rise, the global organ-on-chip market is expected to witness significant growth in the coming years.
Integration of Technologies
The increasing demand for organ-on-chip technology is primarily driven by its unique combination of tissue engineering and microfluidics. This innovative approach not only offers effective solutions to long-standing challenges in individualized disease treatment and medication discovery but also holds immense potential for revolutionizing the field of biomedical research. By replicating the complex structures and functions of human organs, organ-on-chip platforms provide a more accurate and reliable model for drug development studies. This enables researchers to gain deeper insights into the efficacy and safety of potential medications, leading to improved patient outcomes. With its ability to mimic the physiological conditions of specific organs, organ-on-chip technology allows for personalized testing and analysis, paving the way for tailored treatment approaches.
Moreover, the versatility of organ-on-chip technology extends beyond drug development. It holds promise in various areas of research, such as toxicology studies, disease modeling, and precision medicine. By simulating the intricate interactions between cells, tissues, and fluids, organ-on-chip devices enable scientists to investigate complex biological processes in a controlled and reproducible manner. Overall, organ-on-chip technology has the potential to transform the way we approach healthcare. By bridging the gap between traditional in vitro models and animal testing, it offers a powerful tool for accelerating medical research, improving drug discovery, and ultimately enhancing patient care.
Key Market Challenges
Concerns Pertaining due to High Cost of Organ Chip Device
The high cost associated with the organ chip device, coupled with the fact that organ-on-chip (OOC) technology is still in its early stages, is projected to limit the expansion of the market. This is primarily due to the significant investment required for research and development, manufacturing, and commercialization of organ-on-chip devices. The complex nature of the technology, involving the integration of multiple organ models and microfluidic systems, adds to the manufacturing challenges and cost considerations.
Furthermore, certain countries have imposed restrictions on cosmetic testing on animals, which is likely to further hinder the growth of the global organ-on-chip market. In these countries, the government has prohibited the use of animals for testing cosmetics developed within their borders, reflecting a growing awareness and concern for animal welfare. This shift in regulatory policies has prompted the need for alternative testing methods, such as organ-on-chip technology, which can simulate the physiological conditions of human organs and provide more accurate and ethical results.
Availability of Substituents
The availability of the substituent in the market to organ-on-chips is hampering the global market growth in the forecast period. This is because the availability of organoids, which serve the same purpose of mimicking tissue and organ physiology, poses a major hurdle for the organ-on-chip market during this time. Organoids are gaining traction in the market due to their ability to replicate the complex structure and functionality of organs, making them a potential alternative to organ-on-chips.
Furthermore, the increasing developments in the organoids market are presenting threats to the global organ-on-chip market in the upcoming forecast years. For instance, on October 3, 2022, AIM Biotech Pte. Ltd. launched the organiX System, a cutting-edge 3D tissue culture platform. This innovative system enables the addition of vascularization and immune competence to spheroids, tumor biopsies, and organoids, further enhancing their functionality and applicability.
Key Market Trends
Increasing Market Developments
The organ-on-chip market is experiencing significant growth due to various market developments such as product launches, collaborations, mergers, acquisitions, and more. These developments are driving the global market growth in the forecast period.
For example, in September 2021, Fidia Farmaceutici S.p.A. and BiomimX S.r.l. entered into a research collaboration aimed at presenting and introducing new specialized solutions based on Organs-on-Chip to enhance the intra-articular medical device discovery process.
Rapidly Rising Number of Applications
Microfluidic devices and organotypic slices have been combined to improve culture survival in the field of neuroscience research. Traditionally, cultivating organotypic brain slices, which are approximately 300 microns thick, has relied on semi-porous membranes to establish an air-medium interface. However, with the integration of microfluidic technologies, a more sophisticated approach has emerged. These technologies enable the laminar flow of essential nutrients and gases, resulting in enhanced tissue viability and improved transportation within the brain slices.
Segmental Insights
Type
Based on the type, the market for organ-on-chip is predominantly driven by the liver-on-chip model segment, and this trend is expected to persist during the projected period (2024-2028). As the largest internal organ in the human body, the liver plays a crucial role in the synthesis and metabolism of various substances, including drug metabolites.
Modeling the liver has posed challenges due to its diverse range of vital functions, encompassing nutrient and vitamin processing, detoxification, and regulation of bodily metabolism. The limitations inherent in conventional two-dimensional (2D) cell culture techniques for studying pharmacokinetics in hepatic cells (hepatocytes) have yielded suboptimal outcomes in clinical trials and drug development. Recent advancements in microfluidics have facilitated the development of highly
End User Insights
Based on the end user segment, the market is categorized into Pharmaceutical and Biotechnology companies, Academic and Research institutes, and Others, based on the end user. Among these, the pharmaceutical and biotechnology sector significantly contributes to the market. This technique holds immense potential for predicting side effects and the success of drugs and biological products, particularly for the pharmaceutical and biotech industries. The increasing rate of drug approval failures necessitates the development of a comprehensive biological dataset to assess innovative therapies and ensure the safety of novel treatments, where Organ-on-Chip (OoC) technology plays a crucial role. Numerous pharmaceutical and biotechnology firms are leveraging this technique to expedite the discovery and development of novel medications. The market's growth is primarily driven by the growing adoption of Organ-on-Chip technology for drug development by enterprises.
Regional Insights
The North America region is projected to dominate the global market share of organ-on-chip technology. This can be attributed to several factors, including the presence of key pharmaceutical companies, the availability of advanced organ-on-chip models, and favorable government initiatives in terms of funding and programs for drug development and research. The region is also witnessing an increase in targeted diseases such as UI, bladder blockage, urine retention, BPH, and bladder cancer, which further drives the market. Conversely, the Asia Pacific region is expected to experience the fastest growth during the forecast period. Countries like China, India, and Japan present attractive opportunities due to the rising disposable income and increasing adoption of Organ-on-a-Chip technology. Government support for regenerative medicines, along with investments in R&D activities and cell-based clinical trials, are expected to facilitate the expansion of the Organ-on-a-Chip market in the Asia-Pacific region.
Recent Developments
- In June 2023, MatTek Life Sciences announced astrategic partnership with AIM Biotech, facilitating the availability of AIMBiotech's portfolio for sale through MatTek.
- In June 2023, Emulate introduced Emulate Chip-A1â„¢,expanding its applications in the cancer and cosmetic markets.
- In May 2022, Emulate enhanced its intestinalorgan-on-a-chip to support researchers studying inflammatory bowel disease.
- In April 2022, Valo Health completed the acquisition of TARA Biosystems, thecreators of a 3D heart tissue modeling platform. Valo planned to integrateTARA’s heart tissue chips into an end-to-end drug development offeringtargeting cardiovascular disease, leveraging its Opal data platform.
Key Market Players
- Altis Biosystems
- AxoSim Inc.
- BiomimX SRL
- Emulate Inc.
- Hesperos
- Allevi Inc.
- InSphero AG
- MIMETAS BV
- Nortis Inc.
- Hesperos, Inc.
| By Type | By Offering | By Material Type | By Application | By End User | By Region |
|
| Liver Heart Lung Kidney Others | Products Services | Polymer PDMS Glass Silicon Others | Physiological Model Development Drug Discovery Toxicological Research Molecular Biology Others | Hospital & Clinic Home Care Ambulatory Surgical Center | North America Europe Asia Pacific South America Middle East & Africa |
Report Scope
In this report, the Global Organ-on-Chip Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below
- Organ-on-Chip Market, By Type
o
o
o
o
o
- Organ-on-Chip Market, By Offering
o
o
- Organ-on-Chip Market, By Material Type
o
o
o
o
o
- Organ-on-Chip Market, By Application
o
o
o
o
o
- Organ-on-Chip Market, By End User
o
o
o
- Organ-on-Chip Market, By Region
o
o
o
o
o
Competitive Landscape
Company Profiles
found at Customizations
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Global Organ-on-Chip Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy